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Abstract
Background: The number of viral pathogens associated with pediatric acute respiratory tract infection (ARI) has
grown since the introduction of reverse transcription real-time polymerase chain reaction (RT-PCR) assays. Multiple
viruses are detected during a single ARI episode in approximately a quarter of all cases. The clinical relevance of
these multiple detections is unclear, as is the role of the individual virus. We therefore investigated the correlation
between clinical data and RT-PCR results in children with single- and multiple viral ARI.
Methods: Data from children with ARI were prospectively collected during two winter seasons. RT-PCR testing for
15 viruses was performed in 560 ARI episodes. In the patients with a single-viral etiology, clinical data, laboratory
findings, patient management- and outcome data were compared between the different viruses. With this
information, we compared data from children of whom RT-PCR data were negative, with children with single- and
multiple viral positive results.
Results: The viral detection rate was 457/560 (81.6%) of which 331/560 (59.1%) were single infections and 126/560
(22.5%) were multiple infections. In single viral infections, some statistically significant differences in demographics,
clinical findings, disease severity and outcome were found between children with different viral etiologies.
However, no clinically recognizable pattern was established to be virus-specific. In a multivariate analysis, the only
variables that were correlated with longer hospital stay were the use of oxygen and nebulizer therapy, irrespective
of the viral pathogen. Children with RT-PCR positive test results had a significant higher disease severity, fever,
length of hospital stay, days of extra oxygen supply, and days of antibiotic treatment than children with a negative
RT-PCR test result. For children with single- versus children with multiple positive RT-PCR test results, these
differences were not significant.
Conclusions: Disease (severity), management and outcome in pediatric ARI are not associated with a specific virus.
Single- and multiple viral ARI do not significantly differ with regard to clinical outcome and patient management.
For general pediatrics, RT-PCR assays should be restricted to pathogens for which therapy is available or otherwise
may have clinical consequences. Further research with an extended panel of RT-PCR assays and a larger number of
inclusions is necessary to further validate our findings.
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Background
Acute respiratory tract infections (ARI) frequently occur
in young children. Assessment of disease severity is
often difficult and repeated observation over time is rec-
ommended [1]. Most ARI’s in young children are of viral
origin. Traditionally, clinical guidelines on this subject
focus primarily on Respiratory syncytial virus (RSV) and
Influenza virus (FLU), as these are considered the most
significant viral pathogens [1, 2]. Risk factors for a more
severe disease course are best known for RSV [3, 4],
although these fail to predict outcome in individual
patients. Nowadays, real-time reverse transcription poly-
merase chain reaction (RT-PCR) assays have been intro-
duced in many hospitals and the number of viruses
found in nasal wash specimens (NWS) of children with
ARI is growing. The role of many of these viruses in dis-
ease severity and clinical course is still unclear, since
studies differ with regard to design, age at inclusion, re-
cruitment criteria, the manner of data collection, assay
sensitivity and the type of viruses studied [5]. RT-PCR
test results are positive in up to 72–95% of symptomatic
children and up to 40–68% of asymptomatic children,
depending on age, diagnosis and detection method [6].
At the same time, the number of viral co-infections
which are detected by RT-PCR has also grown to 43%
[6]. Interpretation of these test results is even more chal-
lenging. Literature on this subject is growing. Some re-
ports suggest there is no relation between multiple
respiratory viral infections and disease severity [7–11],
while others report a higher disease severity in children
with a multiple respiratory infection [12, 13]. Practical
dilemmas about cohorting of patients with different viral
pathogens have not yet been solved [14].
In a previous controlled clinical trial, we showed that
rapid reporting of RT-PCR test results to the
pediatrician did not influence patient care [15]. The aim
of the current study was to determine if RT-PCR test
results are related to clinical data in children with re-
spiratory symptoms. We investigated clinical symptoms,
management and outcome in these children and corre-
lated these findings to the specific virus determined by
RT-PCR. We additionally investigated clinical differences
between single-, multiple-, and RT-PCR negative ARI.
Methods
Study design
This study is part of the EVIDENCE-trial (Evaluation of
Viral Diagnostics on Respiratory Infections in Children),
a multi-center, controlled clinical trial to evaluate viral
RT-PCR diagnostics for ARI in pediatric patients [15]. In
summary, the trial was conducted during two consecu-
tive winter seasons (2007–2008 and 2008–2009) in two
Dutch teaching hospitals with comparable populations:
the Reinier de Graaf Hospital in Delft joined in the
second season by the Groene Hart Ziekenhuis in Gouda.
The EVIDENCE study-protocol was approved by the
regional Medical Ethics Committee (CCMO number
NL13839.098.06). In the current study, a selection of the
EVIDENCE-dataset is used to analyze the clinical as-
pects in relation to the viral pathogens.
Patients
Children younger than 12 years old with respiratory
symptoms, who visited the emergency department or
pediatric outpatient clinic, were included. More than
90% of these children were assessed by the primary
physician before referral to the hospital. Informed con-
sent for study participation was sought after the NWS
was obtained, because nasal washings are part of stand-
ard diagnostic procedures. Indications for hospital
admission were made on clinical grounds, e.g. need for
extra oxygen, feeding difficulties, apneas as observed by
the parents. Children with underlying anatomical airway
abnormalities (e.g. bronchopulmonary dysplasia) or
other significant underlying disorders (e.g. syndromal
disorders, psychomotor retardation, malignancies) were
excluded. We also excluded newborns that had been
hospitalized since birth. Patients with asthma or sus-
pected asthma were not excluded. Patients could be in-
cluded multiple times during the two study periods,
provided that sampling of NWS was at least 14 days
apart to ensure that the children had a new episode of
ARI. In addition, patient data were reviewed retrospect-
ively to certify that the sample was taken in a second
episode of respiratory symptoms. Patients with positive
RT-PCR results for Chlamydophila pneumoniae, Myco-
plasma pneumoniae and Bordetella pertussis as single or
multiple infection were excluded in order not to trouble
comparisons of the virus groups with respect to clinical
data. Patients with a positive viral RT-PCR and a clinical
confirmed pneumonia were not excluded. Blood cultures
or other bacterial cultures were not standard procedures,
but were performed on clinical grounds. Patient enroll-
ment criteria are presented in Fig. 1.
Definitions
ARI was defined as a new episode of respiratory symp-
toms of the upper and/or lower airways. Upper respira-
tory tract infection (URTI) was defined as any episode of
rhinorrhea, nasal congestion, sore throat, erythematous
pharynx, earache or erythematous eardrum. Lower re-
spiratory tract infection (LRTI) was defined as respira-
tory symptoms with tachypnea and abnormal pulmonary
auscultation; rales, crackles, crepitations, wheezing or
prolonged expiration. Hypoxia was defined as a pulse
oximetric peripheral oxygen saturation of <92% and was
not a criterion for LRTI, as it is involved in URTI as
well. X-ray confirmation also was not used in the
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definition, because of a restricted use of ionizing radi-
ation in pediatric practice. Tachypnea was defined by
age-dependent cut-off values [16]. Wheeze was defined
as high-pitched whistling sound heard coming from the
chest on expiration. Apnea was defined as one or more
episodes of respiratory pauses regardless of duration ob-
served by caretakers, physicians or nurses. Dyspnea was
defined as difficulty of breathing with chest retractions,
use of auxiliary respiratory muscles or nose flaring. In
single-, dual- and multiple infections, RT-PCR was posi-
tive for respectively one, two or more than one virus.
Data collection
Clinical data were prospectively collected with use of a
standardized form by the treating physician. Tables 1, 2
and 3 summarize the data collected. Missing information,
laboratory results and, when available, radiology reports
were retrieved from the patient’s medical electronic record.
Disease severity score (DSS)
The DSS used in this study is a modification of the one
used by Gern et al. [17, 18] (Additional file 1: Table S1). In
the original score, cough and rhinorrhea are subdivided in
mild, moderate and severe. We could not make that sub-
jective distinction in our dataset. Hoarseness was also not
included in our score. In the original score, the maximum
was 31; in our modified score the maximum is 27.
Respiratory pathogens
All samples were tested for RSV with a rapid bedside
test and supplementary RT-PCR assays were performed
for 15 viruses and 2 bacteria (Chlamydophila pneumoniae
and Mycoplasma pneumoniae). RT-PCR for Bordetella
pertussis was performed only on clinical suspicion and
retrospectively in all available samples [19]. A description
of the RT-PCR method and validation procedure is pub-
lished elsewhere [15]. Viral subtypes were clustered into
Fig. 1 Flowchart of Patient enrollment
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virus groups in order to have sufficient patient-numbers
in each virus group. RSV-A and RSV-B were clustered.
Human Coronavirus (HCoV) 229E, HCoV-NL63 and
HCOV-OC43 were clustered. FLU-A and FLU-B were clus-
tered, as well as Parainfluenza virus (PIV) 1, 2, 3 and 4.
Other viruses included rhinovirus (RV, not divided in sub-
groups), Human Metapneumovirus (hMPV), Human
Adenovirus (HAdV) and Human Bocavirus (HBoV). We
did not study SARS Coronavirus, Human Coronavirus
HKU1, enterovirus, Polyomavirus WU and KI.
Other diagnostic procedures
Other diagnostic tests were only performed on clinical
grounds: white blood count, C-reactive protein (Table 3),
blood cultures and X-rays (data not shown).
Statistical analysis
Statistical analysis was performed using IBM SPSS
Statistics 21.0 (SPSS inc., IBM Company, Chicago,
Illinois). For the comparison of categorical or dichot-
omous variables with the pathogen groups, we used
Pearson Chi-squared tests. For the comparison of
continuous variables, we used Kruskal-Wallis- and
MannWhitney tests. For all tests, a p-value <0.05 was
considered significant. Multiple regression analysis
was used to analyze the relation between age, DSS,
LRTI, antibiotic initiated, number of days with antibi-
otics, number of days with extra oxygen, number of
days with nebulization, the virus groups and the out-
come days in hospital. A p-value <0.05 was consid-
ered as significant.
Table 2 Presenting symptoms of single virus infections; parts of the disease severity score
RSV RV hMPV HCoV FLU HAdV HBoV PIV p-value
N = 331 single pathogens 200 30 23 24 21 14 10 9
Fever, n(%) 108(54.3) 9(30.0) 12(52.2) 9(37.5) 17(81.0) 7(50.0) 6(60.0) 5(55.6) 0.030a
Cough, n(%) 187(94.5) 24(80.0) 22(95.7) 13(54.2) 14(66.7) 10(71.4) 9(90.0) 8(88.9) 0.000a
Rhinorrhea, n(%) 190(95.0) 28(93.3) 22(95.7) 22(91.7) 20(95.2) 12(85.7) 10(100.0) 8(88.9) 0.819a
Illness > 4 days, n(%) 180(90.0) 19(63.3) 16(69.6) 13(54.2) 10(47.6) 9(64.3) 8(80.0) 8(100.0) 0.000a
Apnea, n(%) 7(3.5) 1(3.3) 0(0.0) 1(4.2) 0(0.0) 1(7.1) 1(10.0) 0(0.0) 0.789a,b
Wheezing, n(%) 95(47.5) 13(43.3) 6(26.1) 6(25.0) 3(14.3) 6(42.9) 7(70.0) 3(33.3) 0.013a,b
Hypoxia, n(%) 105(52.5) 9(30.0) 9(39.1) 3(12.5) 6 (28.6) 5(35.7) 6(60.0) 5(55.6) 0.003a,b
Dyspnea, n(%) 136(68.0) 16(53.3) 15(65.2) 7(29.2) 5(23.8) 7(50.0) 8(80.0) 6(66.7) 0.000a
Tachypnea, n(%) 123(61.5) 21(70.0) 12(52.2) 12(50.0) 7(33.3) 7(50.0) 10(100.0) 5(55.6) 0.021a
Significant differences are noted as bold (highest) versus italic (lowest) when possible
a Pearson Chi-square tests
b interpret with caution as any cell has a value <5
Table 1 Demographics, clinical characteristics and disease severity score in single virus infections
RSV RV hMPV HCoV FLU HAdV HBoV PIV p-value
N = 331 single pathogens 200 30 23 24 21 14 10 9
Age in months
mean (SD)
5.8 (6.4) 5.4(8.5) 10.2(11.45) 5.1(6.7) 15.1(23.2) 11.8(11.7) 18.6(12.4) 6.8(8.4) 0.001b
Median (IQR) 3.75 (5.56) 2.75(5.4) 4.69(11.84) 2.67(5.62) 2.13(23.53) 6.4(19.79) 15.59(24.58) 5.67(4.87)
Male, n(%) 113(56.5) 18(60.0) 11(47.8) 9(37.5) 11(52.4) 8(57.1) 5(50.0) 4(44.4) 0.638a,c
DSS
mean (SD) 14.9 (6.9) 12.6(7.9) 12.2(7.6) 8.3(6.6) 7.9(7.2) 11.9(8.6) 19.1(3.4) 13.9(8.1) 0.000b
median (IQR) 17.0(10.0) 13.0(15.8) 13.0(16.0) 7.0, 4.0(9.5) 9.0(18.2) 19.0(6.5) 13(16.0)
DSS ≤6, n(%) 27(13.5) 7(23.6) 7(30.4) 10 (41.7) 12(57.1) 5(35.7) 0(0.0) 2(22.2) 0.000a,c
DSS 7–13,n(%) 51(25.5) 10(33.3) 7(30.4) 10(41.7) 5(23.8) 3(21.4) 0(0.0) 3(33.3)
DSS 14–19, n(%) 78(39.0) 5(16.7) 6(26.1) 3(12.5) 2(9.5) 2(14.3) 7 (70.0) 2(22.2)
DSS ≥20, n(%) 44(22.0) 8(26.7) 3(13.0) 1(4.2) 2(9.5) 4(28.6) 3(30.0) 2(22.2)
DSS disease severity score
Significant differences are noted as bold (highest) versus italic (lowest) when possible
a Pearson Chi-square tests
b Kruskal Wallis test
c interpret with caution as any cell has a value <5
Wishaupt et al. BMC Infectious Diseases  (2017) 17:62 Page 4 of 11
Results
Patient enrollment
During the two study periods, a total of 776 NWS were
analyzed. 216 were excluded. In total, 560 viral ARI epi-
sodes (520 patients) were analyzed (flowchart, Fig. 1).
Demographics
The mean age in this study was 7.9 months and
60.5% was male. Single- and multiple infections did
differ significantly in age (7.3 versus 9.0 months, p <
0.001), sex (54.1% versus 64.3% male, p = 0.049) and
daycare attendance (30.8% versus 48.0%, p = 0.002).
Patient reported family history of an atopic constitu-
tion was 56.5% and did not significantly differ be-
tween the virus groups.
Viral results
The detection rate of viruses by RT-PCR was 457/560
(81.6%) (Table 4). Single-infections were detected in 331
out of 560 (59.1%) ARI episodes. Multiple infections
were detected in 126/560 (22.5%) episodes of which 106/
560 (18.9%) were dual infections, 18/560 (3.2%) were
triple infections and 2/560 (0.4%) were quadruple infec-
tions. A negative RT-PCR was present in 103/560
(18.4%) episodes.
RSV was positive in 200/331 single infections (60.4%),
78/106 (73.6%) dual infections and 91/126 (72.2%) multiple
infections. RSV was positive in all of the most frequent
combinations of dual infections (data not shown).
The distribution of the viruses per month is shown in
Fig. 2. Peak incidence of FLU in both seasons was in
January and February. Other viruses were isolated
throughout both winter seasons.
The original study was a randomized controlled clin-
ical trial [15]. A chi-square test showed an equal distri-
bution of the virus groups between intervention- (rapid
reporting of PCR-results to the clinician) and the control
(late reporting) group (data not shown).
Table 3 Outcome, management and laboratory findings in single virus infections
RSV RV hMPV HCoV FLU HAdV HBoV PIV p-value
N = 331 single pathogens 200 30 23 24 21 14 10 9
Hospitalization
admission, n(%) 162(81.0) 22(73.3) 16(69.6) 10(41.7) 16(76.2) 10(71.4) 9(90.0) 7(77.8) 0.004a
days, mean (SD) 4.4(2.8) 3.3(3.1) 3.2(1.5) 3.9(3.4) 2.9(2.7) 2.9(2.1) 3.2(1.9) 5.3(2.7) 0.014b
median (IQR) 4.0 (4.0) 2.0(3.75) 3.0(2.0) 3.0(3.75) 2.0(1.75) 2.0(1.5) 3.0(1.5) 4.0(5.0)
Therapy
AB initiated, n(%) 75(37.5) 7(23.3) 7(30.4) 4(16.7) 7(33.3) 1(7.1) 4(40.0) 6(66.7) 0.029a,c
AB no of days, mean (SD) 2.4(3.3) 1.4(2.7) 2.4(3.9) 1.5(3.6) 2.0(3.0) 0.5(1.9) 2.8(3.6) 3.7(3.3) 0.091b
median (IQR) 0.0(7.0) 0.0(0.8) 0.0(7.0) 0.0(0.0) 0.0(5.0) 0.0(0.0) 0.0(7.0) 3.0(7.0)
Oxygen initiated,n(%) 106(53) 9(30) 9(39.1) 3(12.5) 6(28.6) 5(35.7) 7(60) 5(55.6) 0.062a,c
Oxygen no of days, mean (SD) 2.4(2.7) 1.2(2.2) 1.5(1.7) 1.0(1.8) 0.9(1.5) 1.4(2.1) 1.6(1.3) 2.9(2.9) 0.052b
median (IQR) 2.35(4.0) 0.0(2.5) 1.0(3.0) 0.0(2.3) 0.0(1.8) 0.5(2.5) 2.0(2.0) 3.0(5.0)
Nebulizationd initiated n(%) 63(31.5) 6(20) 6(26.1) 0(0) 3(14.3) 4(28.6) 6(60) 3(33.3) 0.086a,c
Nebulizationd, no of days, mean (SD) 1.2(2.0) 0.7(1.5) 0.8(1.3) 0.0(0.0) 0.4(0.9) 1.4(2.1) 2.2(2.2) 1.3(1.6) 0.050b
median (IQR) 0.0(2.0) 0.0(1.0) 0.0(1.75) 0.0(0.0) 0.0(0.0) 0.0(2.75) 2.0(3.0) 0.0(3.0)
Laboratory
CRP performed, n(%) 111(55.5) 16(33.0) 9(39.1) 14(58.3) 15(71.4) 7(50.0) 4(40.0) 2(22.2) 0.401a,c
CRP max level, mean (SD), mg/L 23.1(25.4) 13.8(19.9) 71.0(117.7) 19.0(44.4) 16.6(18.8) 27.3(36.7) 23.7(26.3) 26.0(31.1) 0.440b
median (IQR) 14.0(37.0) 5.0(25.5) 14.0(112.0) 0.0(14.5) 9.0(25.0) 7.0(63.0) 21.0(48) 26.0(44.0)
CRP > 40, n(%), mg/L 27(13.5) 2(6.7) 3(13.0) 2(8.3) 2(9.5) 2(14.3) 2(20.0) 1(11.1) 0.706a,c
WBC performed, n(%) 26(13.0) 3(10.0) 1(4.3) 0(0.0) 8(38.1) 1(7.1) 1(10.0) 1(11.1) 0.028a,c
WBC max level, mean (SD), 109/L 11.6 (4.5) 9.5 (2.4) 7.6 . 8.1 (2.9) 12.7 13.6 (0.3) 27.0 0.065b
median (IQR) 11.1(6.1) 9.4 7.6(0) . 8.8(5.6) 12.7(0.0) 13.6(0.0) 27.0(0)
AB antibiotics, CRP complement reactive protein, WBC white blood count
Significant differences are noted as bold (highest) versus italic (lowest) when possible
a Pearson Chi-square test
b Kruskal Wallis test
c interpret with caution as any cell has a value <5
d Nebulization with salbutamol and ipratropium bromide
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Clinical symptoms and management of single viral
infections
The overall admission rate in single viral infections was
252/331 (76.1%). Extra oxygen supply was administered
to 149/252 (59.1%) and nebulizer therapy to 91/252
(36.1%) hospitalized children. Although the p-value
indicated a significant difference between the virus
groups with regard to the number of times that antibi-
otics were initiated, it was not possible to explore this
difference using the Pearson Chi-square test. There were
no significant differences between the virus groups with
regard to the mean number of days with antibiotic
Fig. 2 Distribution of virus groups: count per month. Abbreviations: RSV, Respiratory syncytial virus. RV, rhinovirus. hMPV, Human Metapneumovirus.
HCoV, Human coronavirus. FLU, Influenza virus. HAdV, Human adenovirus. HBoV, Human bocavirus. PIV, parainfluenza virus
Table 4 RT-PCR Results in children with acute respiratory tract infections
RT-PCR results N Proportion out
of total
(n = 560 cases)
Detection in single infections Proportion out of
total single
infections (n = 331)
Detection in multiple
infections
Proportion out of total
multiple infections
(n = 126)
Negative 103 18.4%
Single 331 59.1%
Dual 106 18.9%
Triple 18 3.2%
Quadruple 2 0.4%
RSV 291 52.0% 200 60.4% 91 72.2%
RV 72 12.9% 30 9.1% 42 33.3%
HCoV 71 12.7% 24 7.3% 47 37.3%
HAdV 45 8.0% 14 4.2% 31 24.6%
hMPV 42 7.5% 23 6.9% 19 15.1%
FLU 33 5.9% 21 6.3% 12 9.5%
PIV 29 5.2% 9 2.7% 20 15.9%
HBoV 22 3.9% 10 3.0% 12 9.5%
RSV Respiratory Syncytial Virus, RV Rhinovirus, HCoV Human Coronavirus, HAdV Human Adenovirus, hMPV Human metapneuvirus, FLU Influenzavirus, PIV
Parainfluenza virus, HBoV Human Bocavirus
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treatment, extra oxygen supply, nebulizer therapy and
the number of children with feeding problems due to re-
spiratory distress, resulting in a need for tube feeding.
There were also no significant differences between the
virus groups regarding mean or maximum CRP count
and mean or maximum white blood count (Table 3).
The multivariate analysis for length of hospital stay
(LOS) included age, DSS, LRTI, antibiotic treatment,
oxygen therapy, nebulizing therapy and single virus
groups. In the univariate analysis, RSV and RV were the
virus groups that were correlated with longer hospital
stays. In the multivariate analysis, the only variables that
were correlated with longer hospital stays were oxygen
therapy and nebulizer therapy, irrespective of the viral
pathogen. For DSS, there was a significantly adjusted p-
value, whereas the multivariate regression coefficient
was negative (Table 5). In a multivariate sub analysis for
oxygen therapy including RSV, RV and FLU, RSV was
significantly correlated with longer duration of oxygen
therapy (p = 0.020). For nebulizer therapy and duration
of antibiotic treatment, there was no significant correl-
ation with these viruses (data not shown).
The characteristics per virus group are presented in Ta-
bles 1, 2 and 3 and are highlighted per virus group below.
RSV: RSV was the most frequently detected virus and
was found in 200 out of 331 (60.4%) single infections.
The mean age of children with RSV was 5.8 months
and they were significantly younger than children with
FLU or HBoV. RSV positive children were significantly
more often hospitalized than HCoV positive children.
The DSS for children with RSV and HBoV was
significantly higher than for those with HCoV and FLU.
The mean DSS for RSV was 14.9, the second highest
after HBoV (DSS 19.1). This was significantly higher
than for instance FLU (DSS 7.9). Apneas occurred in 7/
200 (3.5%) of RSV single infections. One child was RT-
PCR positive for RSV as single pathogen, despite a first
vaccination with palivizumab. It was a 2 month old boy
born after 32 weeks of gestation with a mild disease
course (DSS 13, LOS 4). None of the children in the
study were treated with the antiviral drug ribavirin.
Rhinovirus: RV was the second most commonly
identified single virus infection (30/331, 9.1%). The
mean age of children with RV was young; 5.4 months.
The DSS was not significantly different compared to
those of other viruses.
Human metapneumovirus: For hMPV, there were no
significant differences compared to the other viruses
with regard to age, DSS and admission rate.
Coronavirus: Children with HCoV had the lowest mean
age (5.1 months) of all virus groups. The mean DSS
was 8.6, which was significantly lower than for RSV or
HBoV. The admission rate was 10/24 (41.7%), the
lowest of all virus groups.
Influenzavirus: The mean age at onset of disease for
FLU was 15.1 months, which was significantly higher
than for RSV and some other viruses. The mean DSS
was 7.9, lowest of all virus groups and significantly
lower than for RSV. None of the patients was treated
with antiviral drugs like oseltamivir.
Adenovirus: For HAdV, there were no significant
differences compared to the other viruses with regard
to DSS and admission rate.
Table 5 Multivariate analysis in single viral respiratory tract infection with regard to Length of Hospital Stay
Univariate Multivariate
Variable Spearman’s ρ p-valuea Regression coefficient Adjusted p-value
Age −0.096 .128 −0.019 0.165
DSS 0.371 <0.01 −0.038 0.052
AB initiated 0.334 <0.01 0.352 0.571
AB no of days 0.336 <0.01 0.026 0.769
FiO2 no of days 0.671 <0.01 0.885 <0.01
Nebulizer 0.120 <0.01 0.293 0.005
RSV <0.01 0.306 0.226
RV 0.022 0.409 0.324
hMPV 0.446
HCoV 0.623
FLU 0.024
HAdV 0.125
HboV 0.470
PIV 0.128
a For continuous variables, Mann-Whitney U tests were used
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Bocavirus: The mean age of children with HBoV was
18.6 months, which was significantly higher than for
RSV, RV and HCoV. The mean DSS was also highest
(19.1), which was significantly higher than for FLU. The
admission rate was 9/10 (90.0%). Although the
admission rate was the highest of all virus groups, this
difference was not significant. The mean number of
days of nebulization therapy with salbutamol and
ipratropium bromide was 2.2 (SD 2.2) days, highest of
all, although this was not significant compared to the
other viruses.
Parainfluenzavirus: The mean DSS for children with
PIV was 13.9, third highest after HBoV and RSV. The
number of times that antibiotics were initiated was
highest for PIV (6/9, 66.7%).
Clinical symptoms and management of multiple viral
infections
Patients with a confirmed viral ARI had a significantly
higher DSS, fever, LOS, extra oxygen supply and anti-
biotic treatment than patients with a negative RT-PCR
result (Table 6). Nebulizer therapy and the admission
rate did not significantly differ between these groups.
Within the group of viral confirmed ARI, children
with single- and multiple viral infections did not signifi-
cantly differ with regard to DSS, fever, admission rate,
LOS, extra oxygen supply, nebulizer therapy and dur-
ation of antibiotic treatment when initiated (Table 6).
Sub analysis per group was performed for RT-PCR nega-
tive, single-, dual-, triple- and quadruple infections. No
significant differences were found (data not shown).
A sub analysis of the five most common dual viral
combinations (RSV/HCoV, RSV/RV, RSV/HAdV, RSV/
hMPV, RSV/PIV) was performed in order to investigate
whether these groups differed in clinical symptoms and
management. There were no significant differences be-
tween the groups with regard to DSS (p = 0.958), admis-
sion rate (p = 0.318), LOS (p = 0.906), extra oxygen
supply (p = 0.456), nebulizer therapy (p = 0.210) and anti-
biotic treatment (p = 0.339) (data not shown).
Discussion
In this study, we investigated clinical presentation, man-
agement and outcome in a large cohort of patients with
viral ARI and correlated these findings to the specific
virus that was established by RT-PCR. Despite some sig-
nificant differences, no clinically recognizable pattern
per virus group was found. In addition, we showed that
children with single- and multiple viral ARI did not dif-
fer with regard to clinical outcome.
Single infections
The high number of RSV positive children, their young
age, high admission rate and high DSS was expected
since RSV is well known to have a great disease burden
in young children [20]. RV usually is the most frequently
found virus in young children and Enteroviridae peak in
late summer and autumn [21]. However, in our study,
RV was not frequently found as a single pathogen, pos-
sibly due to the sampling period in the winter. The high
admission rate and moderate DSS stresses the growing
evidence that RV is associated with a more severe ARI
in young children [22–24].
In our study, clinical data of patients with hMPV did
not differ to patients with other viruses. This is in line
with literature, in which patients with RSV and hMPV
were virtually indistinguishable with regard to symptoms
and laboratory findings [25]. We did not find the typical
male to female ratio of two to one, as reported earlier [26].
For the Coronavirus group, DSS, percentage of hospi-
talizations, the number of days with extra oxygen and
the number of days with nebulization was low, suggest-
ing a mild disease course. This was in contrast with the
relative high median number of days in hospital. Only
one specific patient was responsible for this effect. It was
a 2 year old boy with a double sided pneumonia, DSS
19, maximum CRP 51 mg/ml, treated with intravenous
antibiotics for 7 days.
The mean age of children positive for FLU was rela-
tively high and most children were infected during the
second winter season in their life. A possible explanation
for this phenomenon is that the influenza-season lasts
Table 6 Clinical symptoms and management in RT-PCR negative, positive, single- and multiple ARI
RT-PCR negative RT-PCR positive p-valuea Single ARI Multiple ARI p-value
DSS, mean 8.83 13.83 0.000 13.57 14.51 0.243
Fever n/total (%) 37/103 (35.9) 243/457 (53.2) 0.002 173/331 (52.3) 70/126 (55.6) 0.529
Admission n/total, (%) 74/103 (71.8) 342/457 (74.8) 0.530 252/331 (76.1) 90/126 (71.4) 0.300
LOS (days) 2.99 3.95 0.003 4.02 3.76 0.432
Oxygen supply (days) 0.85 1.98 0.000 1.99 1.96 0.912
Nebulizer therapy (days) 1.03 1.19 0.227 1.10 1.46 0.140
Antibiotics (days) 1.56 2.32 0.041 2.19 2.67 0.190
ARI acute respiratory tract infection, RT-PCR reverse-transcriptase real-time polymerase chain reaction, DSS disease severity score, LOS length of hospital stay
a Significant differences are noted as bold
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only a few weeks during a winter season [21]. As adults
are also frequently infected, young children may be pro-
tected by circulating maternal antibodies against FLU
during the first months of their life [27]. The low DSS
for FLU was also remarkably as FLU is considered a po-
tential virulent pathogen, especially in young children
[2]. Possibly our inclusion criteria (children with ARI)
may miss children with fever without a source or a sep-
sis like syndrome as is frequently seen in young children
with influenza. Another important note is that our inclu-
sion period was before the FLU-A H1N1 2009 pandemic
occurred. The circulating FLU-A strains have changed
in composition and this may have an effect on the clin-
ical presentation of FLU nowadays. A recent study
showed a more severe disease course in children with
FLU-A compared to FLU-B [28].
The DSS for HBoV was high in our study. Similar re-
sults were found in a recent study showing that HBoV
as a single pathogen can cause severe ARI [29]. The
mean age of children with HBoV in our study was sig-
nificantly higher than for children with RSV, RV and
HCoV, which has not been reported before. A possible
explanation is again protection by maternal antibodies.
As reviewed by Jartti, protection by vertical antibody
transfer is common at age < 2 months. After this age
HBoV antibody-titers decline and are lowest at age 6–12
months. After 12 months seroprevalence of HBoV in-
creases again until age 6 years. At that time almost all
children have circulating HBoV antibodies [30].
Apneas are an important concern in young children
with bronchiolitis. In our study, apneas occurred in
seven out of 200 (3.5%) RSV single infections, compar-
able with data found in a recent review [31]. However,
apneas occurred also in non RSV-infections (4/131,
3.1%). The clinical data and risk factors for children with
apneas have been published elsewhere [18].
Although we showed some significant differences in
clinical data between the virus groups, a specific clinic-
ally recognizable pattern per virus group could not be
defined. All virus groups showed overlapping clinical
symptoms.
Multiple infections
Patients with a positive RT-PCR result were different
from children with a negative RT-PCR result, except for
admission rate and nebulization therapy (Table 6). A
possible explanation is that asthma patients were not ex-
cluded in this study and nebulization therapy is some-
times started as test treatment in children with ARI and
wheezing episodes. Patients with multiple infections
were significantly older than patients with single infec-
tions, as is also previously reported [11, 32]. A possible
explanation is a higher daycare attendance in older
children, where crowding of children leads to virus
transmission [33, 34]. Indeed, in our study daycare at-
tendance appeared more often in children with a
multiple infection.
General discussion
Patients could be included multiple times in our study.
To ensure that this was not in the same period of illness,
an interval of at least 14 days between two NWS sam-
ples was chosen. In a sub analysis of the repeat cases,
RT-PCR showed different viruses in 34 out of 35 pa-
tients between the first and second illness period. In one
patient, both NWS were positive for RSV-A, but these
samples were taken in different years. In 22 out of these
35 patients, RT-PCR was positive for multiple viruses.
There is increasing interest in the importance of viral
load. Whether viral load, determined by cycle threshold
values of RT-PCR assays may contribute to disease se-
verity and/or to a better understanding of the role of
multiple infections lay outside the scope of this study.
This subject will be addressed in a separate paper.
A limitation of this study is the small number of pa-
tients in some virus groups, even after clustering of viral
subtypes. This might have led to over- or underestima-
tion of some effects. The clustering of different virus
subtypes itself could potentially lead to underestimation
of some more harmful subtypes. Some investigators
showed a more severe disease course of RV subtype C
[35], while others found a similar disease severity be-
tween subtypes A and C [36]. Our RT-PCR assay could
not differentiate between different subtypes of RV. For
RSV, an equal disease severity between the subtypes A
and B is assumed [37]. We clustered FLU-A and FLU-B,
and as mentioned above, inclusion of patients was before
the FLU-A H1N1 2009 pandemic occurred. Secondly,
bias may have been introduced in our study since most
children were referred to the hospital only after initial
assessment by a primary care physician, as is common in
the Dutch healthcare system. Therefore, patients with
milder disease may be underrepresented; this is also
reflected in the high admission rate of 76.1% in single-
infections and 74.3% in all ARI’s in this study. We used
a modified scoring system to avoid subjective terms like
moderate or severe. A concern in the interpretation of
clinical severity using a DSS is the lack of uniformity be-
tween scoring systems for young children with ARI in
literature. The severity score of Gern et al. was also used
in a study correlating viral load and disease severity of
RSV patients [38]. We also used a modification of this
scoring system in a recent study [18]. Another concern
is the lack of uniformity of case-definitions. A strict
definition of URTI (ear, nose, throat region) or LRTI
(bronchi and lung tissue) is difficult in young children,
since classical criteria like tachypnea and hypoxia are not
restricted to LRTI.
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Conclusion
In conclusion, clinical management and outcome in chil-
dren with ARI are not determined by the type of virus.
Children with one specific virus do not have a specific
clinically recognizable pattern and children with single-
and multiple viral ARI are clinically indistinguishable.
LOS is determined by duration of extra oxygen supply
or need for nebulizer therapy. The impact of RT-PCR
for special indications is outside the scope of this paper
as is the role of RT-PCR for other clinical purposes such
as management of cohorting of inhospital patients. How-
ever, at this moment, for the general pediatric patient
management the impact seems limited. In these settings,
RT-PCR assays should be restricted to pathogens for
which therapy is available, e.g. the clinical course can be
influenced, such as for RSV, FLU and Bordetella pertussis.
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